Pfizer Announces Primary Endpoints Met in Second Phase 3 Clinical Trial of Tofacitinib
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) announced that the ORAL Sync Phase 3 study (A3921046) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis (RA), met its primary endpoints
Bayer extends support to fight Chagas disease
- Details
- Category: Bayer
Bayer HealthCare today signed an extension of its agreement with the World Health Organization (WHO) to fight Chagas disease, a deadly and neglected tropical disease (NTD). The five-year extension will come into effect in April 2012, when the previous agreement signed in 2007 had been set to expire.
Breakaway From Cancer(R) Launches Newly-Enhanced Website
- Details
- Category: Amgen
As part of its ongoing mission to serve cancer patients, Amgen's Breakaway from Cancer(R) initiative announced the launch of its enhanced website that provides cancer patients, survivors, and caregivers a 'one-stop shop' of essential resources spanning cancer prevention, education, patient care, advocacy, and financial support.
Breaking the Taboo Associated with Hemorrhoidal Disease
- Details
- Category: Bayer
Experts assume that more than 50 percent of Americans over the age of 50 have had symptoms related to hemorrhoidal disease at some point in their lives(1).
Nycomed well positioned in emerging markets
- Details
- Category: Nycomed
Nycomed's 2010 performance continued to show above industry average growth in emerging markets, as well as strong growth of Key Products (excluding pantoprazole), Regional and Local prescription (Rx) drugs.
Roche Annual General Meeting: dividend raised by 10%
- Details
- Category: Roche
Roche's Annual General Meeting, which was held in Basel, has approved all of the Board of Directors' proposals. The 818 shareholders in attendance, representing 142,963,212 or 89.4% of a total of 160,000,000 bearer shares, approved the 2010 Annual Report and financial statements.
Nycomed's novel COPD therapy roflumilast receives FDA approval
- Details
- Category: Nycomed
Nycomed's US partner Forest Laboratories, Inc. (NYSE: FRX) announced that DalirespTM (roflumilast) was approved by the US Food and Drug Administration (FDA) as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations
More Pharma News ...
- Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program
- Results Published in The Lancet Demonstrate Superiority of XGEVA(TM) (Denosumab)
- Bayer and Onyx Initiate Phase III Trial of Nexavar® in Combination with Chemotherapy
- Lundbeck delivers at the top-end of guidance and momentum is expected to continue in 2011
- Sanofi Pasteur and International Vaccine Institute Partner against Dengue
- ONGLYZA™ US label update regarding use in renally impaired adults with type 2 diabetes
- Forest Laboratories to Acquire Clinical Data, Inc.